About The Study:

Pneumococcal bacteria cause many different types of infections such as meningitis, bloodstream infections (sepsis), pneumonia, meningitis, and ear infections. Older adults who are experiencing other health complications have a higher risk of contracting pneumococcal disease and in turn, a higher death rate. Currently, there are three different vaccines to protect against pneumococcal diseases (Prevnar 13, Pneumovax 23, and Prevnar 20). However, the three existing vaccines only cover a select few strains that cause infection. There is a need for a better vaccine to protect against the emergence of additional strains of the disease. 

The purpose of this study is to test an adjuvant-added pneumococcal vaccine so that it can cover more strains of the bacteria and provide more effective protection. 

The study will last between 12-13 months long and include 4-6 visits to our office and 0-2 telephone calls. Compensation for this study will be provided if you qualify to participate. Study-related care is available to participants at no cost and health insurance is not required nor needed.


  • Are between the ages of 50-64 years old
  • Generally healthy (no serious chronic disorders)
  • Have had no previous pneumococcal vaccines (including an investigational study)
  • *Please note, that other qualifications apply